ResMed Inc. (LON:0KW4)
249.70
+0.99 (0.40%)
At close: Nov 7, 2025
ResMed Revenue
ResMed had revenue of $1.34B USD in the quarter ending September 30, 2025, with 9.07% growth. This brings the company's revenue in the last twelve months to $5.26B, up 9.36% year-over-year. In the fiscal year ending June 30, 2025, ResMed had annual revenue of $5.15B with 9.84% growth.
Revenue (ttm)
$5.26B
Revenue Growth
+9.36%
P/S Ratio
7.13
Revenue / Employee
$495.98K
Employees
10,600
Market Cap
27.88B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.15B | 461.03M | 9.84% |
| Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
| Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
| Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
| Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
ResMed News
- 6 days ago - RMD: Baird Lowers Price Target for ResMed to $300 While Maintaining Outperform Rating | RMD ... - GuruFocus
- 8 days ago - RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News - GuruFocus
- 8 days ago - Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD Stock News - GuruFocus
- 9 days ago - Mizuho Maintains 'Outperform' for RMD but Lowers Price Target | RMD Stock News - GuruFocus
- 9 days ago - These Analysts Revise Their Forecasts On ResMed Following Q1 Results - Benzinga
- 9 days ago - These Analysts Revise Their Forecasts On ResMed Following Q1 Results - Benzinga
- 9 days ago - ResMed declares $0.60 dividend - Seeking Alpha
- 9 days ago - Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand - Nasdaq